Trial Profile
A pilot study of continuous imatinib versus pulsed imatinib with or without lenograstim in chronic myeloid leukaemia patients who have achieved a complete cytogenetic response
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jun 2023
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Lenograstim
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- Acronyms GIMI
- 30 Aug 2014 New source identified and integrated (United Kingdom Clinical Research Network record: 1451)
- 30 Aug 2014 According to the United Kingdom Clinical Research Network record, accrual to Date is 100%
- 19 May 2006 New trial record.